CAS No: 224785-91-5
Appearance: White powder, odorless, taste bitter and astringent soluble in water and alcohol.
Use: It is pharmaceutical raw material, indicated for the treatment of erectile dysfunction
White or almost white crystalline powder
White crystalline powder
Loss of drying
Only one spot
Only one spot
It complies with the USP 32.
The treatment of erectile dysfunction is a first-line treatment for erectile dysfunction. Developed by the German Bayer company, it was first launched in the US in 2002. Like sildenafil, it belongs to the second generation of type 5 phosphodiesterase inhibitors. It works very quickly and takes about 15~20 minutes. The effect is ten times stronger than that of sildenafil. Clinical data show that 50% to 60% of male diabetic patients over 50 years of age have erectile dysfunction, and erectile dysfunction caused by nerve and vascular injury caused by diabetes is particularly difficult to cure. Bayer, a powerful selective phosphodiesterase 5 (PDE5) inhibitor, is likely to bring the gospel to patients with erectile dysfunction caused by diabetes. As a one-time treatment drug, these drugs are taken orally about 1 hours before sexual life. By selectively inhibiting PDE5 and blocking the release of nitric oxide (NO) induced cGMP degradation after sexual stimulation, it improves the concentration, relaxes the arterial smooth muscle, strengthens the erectile function, and occasionally has a headache, blushing, stomach discomfort, and color. Adverse reactions such as disturbance of consciousness.
Three selective type 5 phosphodiesterase (PDE5) inhibitors: sildenafil (sildenus), favdenafil (eolda) and TDA are the first-line drugs for the treatment of ED; there is no significant difference between PDE5 inhibitors and apomorphine in the efficacy, safety, and tolerance of the drug; the injection of prostaglandins in the cavernous body E1 is a second-line treatment for ED, while prostaglandin E1 in the urethra is less effective than intravitreal injection of prostaglandin E1. It is concluded that PDE5 inhibitors are effective, well tolerated and safe in the treatment of ED, and the treatment of apomorphine, injection of prostaglandin E1 and urethral prostaglandin E1 in the urethra is also effective and is well tolerated.